$JNJ Recent News The best way to get into the

New Post Public Reply Private Reply Replies (0) Message Board

Feb 10, 2015 at 12:37 PM

$JNJ Recent News

The best way to get into the drug-distribution space 1:20 p.m. Feb. 5, 2015 - The Trading Deck
The most important thing to look for in Amazon’s earnings 12:35 p.m. Jan. 29, 2015 - Ophir Gottlieb
FDA gives investors another reason to like DexCom 11:30 a.m. Jan. 29, 2015 - The Trading Deck
20 dividend stocks to help you rise above low interest rates 11:09 a.m. Jan. 23, 2015 - Philip van Doorn
What happens if the ECB pulls a Swiss-style surprise 7:30 a.m. Jan. 21, 2015 - Barbara Kollmeyer
Updates, advisories and surprises 7:01 p.m. Jan. 20, 2015 - MarketWatch
Netflix surges after earnings, subscriber growth beats 6:33 p.m. Jan. 20, 2015 - Victor Reklaitis
Stocks eke out gains in choppy trade 4:34 p.m. Jan. 20, 2015 - Carla Mozee
Johnson & Johnson sales dented by stronger dollar 12:49 p.m. Jan. 20, 2015 - MarketWatch.com
J&J shares drop 2.2% for biggest loss among Dow stocks 9:34 a.m. Jan. 20, 2015 - Victor Reklaitis
Tue., Jan. 20: Watch Twitter on India Deal 9:32 a.m. Jan. 20, 2015 - MarketWatch
Morgan Stanley Misses on Q4 Earnings 9:30 a.m. Jan. 20, 2015 - MarketWatch
Johnson & Johnson beats profit expectations, but sales fall shy 7:59 a.m. Jan. 20, 2015 - Tomi Kilgore
Johnson & Johnson's stock slips 0.3% permarket after Q4 results 7:50 a.m. Jan. 20, 2015 - Tomi Kilgore
Johnson & Johnson Q4 Remicade sales $1.67 vs. FactSet consensus $1.74 7:50 a.m. Jan. 20, 2015 - Tomi Kilgore
Johnson & Johnson Q4 sales down 0.6% to $18.3 bln; FactSet consensus $18.56 bln 7:48 a.m. Jan. 20, 2015 - Tomi Kilgore
Johnson & Johnson net EPS 89 cents vs. $1.23 a year ago 7:47 a.m. Jan. 20, 2015 - Tomi Kilgore
Johnson & Johnson Q4 adj. EPS $1.27 vs. FactSet consensus $1.25 7:46 a.m. Jan. 20, 2015 - Tomi Kilgore
Earnings, ECB highlight holiday-shortened week 2:50 a.m. Jan. 19, 2015 - Tom Bemis
J&J gets grant to speed up Ebola vaccine 8:13 a.m. Jan. 16, 2015 - Chelsey Dulaney

Total Return Of Stocks With The Largest Following On Seeking Alpha 7:42 a.m. Today - Seeking Alpha
Going Overweight With Gilead In My DGI Portfolio 4:33 p.m. Feb. 9, 2015 - Seeking Alpha
The 4 Stocks That Weighed Down The DJIA on Monday 3:45 p.m. Feb. 9, 2015 - 247WallSt.com
Best Stock Picks For New Investors 2:57 p.m. Feb. 9, 2015 - GuruFocus.com
The Best Fund Families: A Barron’s Exclusive 12:55 p.m. Feb. 9, 2015 - Barrons.com
Own The Portfolio Of The One Percent 7:56 a.m. Feb. 9, 2015 - Seeking Alpha
Johnson and Johnson, Inc. (JNJ): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Feb. 9, 2015 - Zacks.com
4 Reasons to Buy Misunderstood JNJ Stock 12:00 a.m. Feb. 9, 2015 - InvestorPlace.com
Drug Making Breaks Away From Old Ways 8:07 p.m. Feb. 8, 2015 - The Wall Street Journal Interactive Edition
In Perspective: The Ridiculously Large Market Caps Of America's 20 Most Valuable Companies 10:33 a.m. Feb. 8, 2015 - Seeking Alpha
The 4 Stocks That Sank the Dow on Friday 4:04 p.m. Feb. 6, 2015 - 247WallSt.com
Smith & Nephew's Shares Are Risky, Despite the Company's Strong Outlook 3:31 p.m. Feb. 6, 2015 - TheStreet.com
Retirement Strategy: The Frothy Market Beginners Portfolio Grows Cash By Doing Nothing But Owning Shares 11:21 a.m. Feb. 6, 2015 - Seeking Alpha
Is Boston Scientific Worth the Risk? 8:45 a.m. Feb. 6, 2015 - Barrons.com
Pfizer Buying Hospira To Inject Growth Into Generics 4:27 p.m. Feb. 5, 2015 - Investors Business Daily
Stocks Hold Highs as Crude Oil Recovers $50 on Bets of Global Growth 3:16 p.m. Feb. 5, 2015 - TheStreet.com
More Proof of Accelerating Boston Scientific Turnaround 1:24 p.m. Feb. 5, 2015 - 247WallSt.com
Predictable Fast Growing Healthcare Dividend Growth And Growth Stocks For Your Retirement Portfolios: Part 5 11:51 a.m. Feb. 5, 2015 - Seeking Alpha
Pfizer to Buy Hospira for $16 Billion 11:51 a.m. Feb. 5, 2015 - The Wall Street Journal Interactive Edition
Big Pharma Weak Guidance Put These ETFs in Focus - ETF News And Commentary 11:00 a.m. Feb. 5, 2015 - Zacks.com

BRIC Traditional Wound Management Market Outlook to 2020 1:37 p.m. Feb. 9, 2015 - PR Newswire - PRF
Advanced Remote Patient Monitoring Systems, 7th Edition 12:56 p.m. Feb. 9, 2015 - PR Newswire - PRF
McPhadden Samac Tuovi LLP Commences Xarelto Class Action Against Bayer and Janssen 1:32 p.m. Feb. 6, 2015 - Marketwired
Johnson & Johnson Chief Procurement Officer Named as ISM Board Chair 9:00 a.m. Feb. 5, 2015 - PR Newswire - PRF
INC Research Further Strengthens Board of Directors Through Appointment of Pharmaceutical Executive David Norton 2:30 p.m. Feb. 4, 2015 - GlobeNewswire
Marathon Pharmaceuticals Names Greg Aronin Vice President of Government Affairs 9:30 a.m. Feb. 3, 2015 - BusinessWire - BZX
Target, Dow, 3M, Pepsi and More Headline SUSTPACK 2015 11:35 a.m. Jan. 29, 2015 - BusinessWire - BZX
Applied Molecular Transport Announces Research and Development Collaboration with Janssen and Johnson & Johnson Innovation for Novel Therapeutic Candidate to Treat Inflammatory Bowel Diseases 8:30 a.m. Jan. 28, 2015 - PR Newswire - PRF
Young Men Allege Prescription Drug Risperdal Linked to Abnormal Male Breast Development 12:30 p.m. Jan. 27, 2015 - BusinessWire - BZX
Dr. Paul Janssen Award for Biomedical Research Issues 2015 Call for Nominations 9:00 a.m. Jan. 21, 2015 - PR Newswire - PRF
InvestorsObserver releases comments on Johnson & Johnson, American Express, Delta Air Lines, Broadcom Corp., and Meritage Homes 9:31 a.m. Jan. 20, 2015 - PR Newswire - PRF
New Provisional Patents Filed for Pharmaceutical Cannabidiol (CBD) Formulation Consisting of Ibuprofen & CBD Compounds Aimed At Treating Pain 8:45 a.m. Jan. 20, 2015 - PR Newswire - PRF
Johnson & Johnson Reports 2014 Fourth-Quarter and Full-Year Results: 7:45 a.m. Jan. 20, 2015 - PR Newswire - PRF
Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution 4:05 p.m. Jan. 15, 2015 - PR Newswire - PRF
Wearable Technology in Industry Verticals 2014 - 2019 4:45 p.m. Jan. 14, 2015 - PR Newswire - PRF
DECN Plans New Legal Challenge After LifeScan (J&J) Admits to Using Sworn Testimony From Expert With Falsified Credentials 9:20 a.m. Jan. 14, 2015 - Marketwired
Tissue Regeneration Systems Adds Business Development Executive 5:00 a.m. Jan. 14, 2015 - PR Newswire - PRF
LeeAnn Ali Joins BioBridges as Executive Director, Clinical Operations 8:03 a.m. Jan. 13, 2015 - Marketwired
Janssen and Johnson & Johnson Innovation Announce License Agreement with Vedanta Biosciences for Microbiome Pharmaceutical Candidate for Inflammatory Bowel Disease 8:02 a.m. Jan. 13, 2015 - BusinessWire - BZX
Vedanta Biosciences Announces License Agreement with Janssen and Johnson & Johnson Innovation for Microbiome Pharmaceutical Candidate for Inflammatory Bowel Disease 8:00 a.m. Jan. 13, 2015 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Home Insurance Gaps: Risky Assumptions Uncovered

Unseen Threats to Homeownership Safety Liability gaps in insurance are like those stubborn stains on the carpet you keep missing—nearly invisible until you're flat on your face. In Alpharetta and Fulton County, homes aren't as secure from financial pitfalls as their charming façades suggest. So, what's the danger that folks are glossing over here? Hidden Dangers of...

Pathalys' Phase 3 Data Shows Promise for CKD Drug

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

Enigmata Innovates AI Security with Finovifi Tie-Up

Emerging AI Risks and Protective Measures AI in financial spaces is like walking a tightrope, there's potential but caution is crucial. Enter Enigmata, diving headfirst into this arena by shaking hands with the Finovifi Marketplace. Their aim? To bolster AI's promise without letting sensitive data slip through the cracks. Sentinel: A New Guard for Sensitive Data Let's not...

Northern Virginia's Housing Inventory Surges Despite Market Pressures

Unexpected Surge in Northern Virginia's Inventory Walking around Fairfax these days, you might feel like you're in a time warp, especially if you're tracking the housing market. See, while the rest of the country's housing market groans under sluggish sales and creeping prices, Northern Virginia's doing a dance of its own. Inventory's ballooning faster than a parade...

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Monterey Desalination Project: Costs, Challenges & Future

Water Woes Dragging on in Monterey? Alright, let's dive into the nitty-gritty of this water supply saga in the Monterey Peninsula. If you're wondering why California American Water is hustling so hard, it's because the taps around here ain't running like they should. This mess has been stretching on for ages, with everyone thirsty for a sustainable answer. The Cost of...

Empire Steak House Expands to Delray Beach

Steakhouse Kings Bring New York Flavors to Florida When you're talking about steak, the Empire Steak House name carries some serious heft. This isn't just another restaurant chain cashing in on prime cuts; it's a family legacy over 21 years in the making. The Sinanaj Brothers, who honed their skills at Peter Luger in New York, are moving their empire south, landing a...

CapCut's AI Tools Reshape Video Content Creation

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Callender Bowlin's Legal Eagles Soar in Texas 2026

The Spotlight on CB Trial's Legal Titans Roll the dice, folks—who stands up in Texas’ legal playground? It's Callender Bowlin, PLLC's hotshots again securing their hallmark in the 2026 Texas Super Lawyers gauntlet. This ain’t their first rodeo, either. Founding partners Mark Callender and Josh Bowlin—names synonymous with high-stakes litigation—continue to bask...

Apalutamide Boosts Outlook for Prostate Cancer Treatment

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...